Rolapitant

29 interactions 4 explained in plain English

Also sold as: Varubi

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 4, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Colchicine Digoxin Morphine Injection Cyclosporine Ophthalmic Nebivolol Brexpiprazole

1 Contraindicated 15 Major 13 Moderate

All (29) Contraindicated (1) Major (15) Moderate (13)

Contraindicated

Rolapitant Colchicine Colcrys Explained Increased colchicine exposure and an increased risk of colchicine toxicity Details

Major

Rolapitant Acetaminophen And Codeine Capital® & Codeine Explained Increased codeine exposure and reduced active metabolite (morphine) exposure Details Rolapitant Abametapir Explained Increased exposure of CYP3A4 substrate Details Rolapitant Relugolix Orgovyx Explained Increased relugolix exposure Details Rolapitant Alpelisib Piqray Increased alpelisib exposure and an increased risk of alpelisib-related adverse effects and toxicity Details Rolapitant Brexpiprazole Rexulti Increased brexpiprazole exposure Details Rolapitant Cyclosporine Injection Atopica Increased cycloSPORINE exposure Details Rolapitant Cyclosporine Ophthalmic Cequa Increased cycloSPORINE exposure Details Rolapitant Dabigatran Pradaxa® Increased dabigatran exposure and an increased risk of bleeding Details Rolapitant Dabigatran Etexilate Increased dabigatran exposure and an increased risk of bleeding Details Rolapitant Digoxin Cardoxin® Increased digoxin exposure Details Rolapitant Lefamulin Xenleta Increased lefamulin exposure and an increased risk of lefamulin-related adverse reactions Details Rolapitant Letermovir Injection Prevymis Increased CYP3A substrate exposure Details Rolapitant Loperamide Diamode An increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Rolapitant Morphine Injection Astramorph® PF Increased morphine exposure and an increased risk of morphine-related adverse effects (hypotension, respiratory depression, profou... Details Rolapitant Nebivolol Bystolic Increased exposure to nebivolol Details

Moderate

Rolapitant Clopidogrel Plavix Reduced clopidogrel active metabolite exposure and reduced platelet inhibition Details Rolapitant Docetaxel Beizray Increased docetaxel exposure Details Rolapitant Docetaxel Injection Beizray Increased docetaxel exposure Details Rolapitant Doxorubicin Adriamycin Increased DOXOrubicin exposure Details Rolapitant Epirubicin Ellence Increased epirubicin exposure Details Rolapitant Fluorouracil Adrucil Increased fluorouracil exposure Details Rolapitant Fluorouracil Injection Adrucil Increased fluorouracil exposure Details Rolapitant Fluorouracil Topical Carac Increased fluorouracil exposure Details Rolapitant Irinotecan Camptosar Increased irinotecan exposure Details Rolapitant Irinotecan Injection Camptosar Increased irinotecan exposure Details Rolapitant Irinotecan Lipid Complex Injection Onivyde® Increased irinotecan exposure Details Rolapitant Methotrexate Jylamvo Increased methotrexate exposure Details Rolapitant Methotrexate Injection Abitrexate® Increased methotrexate exposure Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.